Guy Young/LinkedIn
Jan 2, 2026, 03:50
Emicizumab in Infants: Not Just Cost-effective but Mandatory
Flora Peyvandi, Professor of Internal Medicine at the University of Milan and former President of ISTH, shared a post on X:
“Emicizumab in infants: not just cost-effective but mandatory.”
Author: Guy Young
Read the full article.
More posts by Flora Peyvandi on Hemostasis Today.
-
Oct 21, 2026, 10:33Karen Schreiber: Beyond Clinical Outcomes – The Voices of Women with APS
-
Oct 21, 2026, 10:11Tau Braun: Clots Through the Copper-Zinc Model
-
Oct 21, 2026, 09:55Cristina Figueroa Villalba: Celebrating Excellence in Transfusion Medicine
-
Oct 21, 2026, 09:43Ahmad Gharehbaghian: How Can Blood Supplies Be Sustained During a Crisis?
-
Oct 21, 2026, 09:30Adrián Dante De Angelis: Research That Opens New Possibilities for Recurrent iTTP
-
Oct 21, 2026, 09:13Jarod Horobin: Blood 2026 – Connecting Science and People
-
Oct 21, 2026, 08:35Raeeda Gheewala: VTE in Athletes – Risks Beyond the Playing Field
-
Oct 21, 2026, 08:29Andreas Kronbichler: The Changing Landscape of CV Risk in ANCA-Associated Vasculitis
-
Oct 21, 2026, 08:21Pham Quy: Taking Stroke Awareness Beyond Hospitals and Into the Community